LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Eligible for screening study DCP 001
A012301 is closed to accrual, effective May 12 ,2026, at 4:30pm ET.
A012301 is closed to accrual to the Imaging Sub Study (A012301-IM1), effective September 9, 2025.
Montana Cancer Consortium will not be participating in the ICAREdata® project in this protocol.
